Abstract

Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with cancer.

OriginalsprogEngelsk
TidsskriftCancer Cell
Vol/bind41
Udgave nummer4
Sider (fra-til)649-650
ISSN1535-6108
DOI
StatusUdgivet - 10. apr. 2023

Bibliografisk note

Copyright © 2023 Elsevier Inc. All rights reserved.

Fingeraftryk

Dyk ned i forskningsemnerne om 'BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer'. Sammen danner de et unikt fingeraftryk.

Citationsformater